Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company specializing in augmented intelligence (AI) for chronic low back pain, announced on May 6, 2026, that it granted an inducement stock option to Daniel Keefe, its newly appointed Commercial Director for the Western U.S. The grant, approved by the compensation committee of Aclarion’s board of directors on May 5, 2026, covers 17,000 shares of common stock at an exercise price of $3.20 per share, equal to the closing price on the grant date.
The stock option was offered as an inducement material to Mr. Keefe’s employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests over four years: one-fourth on the one-year anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on continued service. The option carries a 10-year term and is governed by an inducement stock option agreement.
This move signals Aclarion’s strategic expansion of its commercial team in the Western U.S., driven by what the company describes as “triple-digit growth in utilization” of its Nociscan platform. Nociscan is a Software-as-a-Service (SaaS) platform that uses magnetic resonance spectroscopy (MRS) data from MRI machines, proprietary signal processing, and AI algorithms to help physicians noninvasively identify painful versus nonpainful discs in the lumbar spine. By extracting chemical biomarkers associated with disc pain, Nociscan provides critical insights to optimize treatment strategies for chronic low back pain.
For business and technology leaders, the implications are significant. Chronic low back pain is a leading cause of disability worldwide, and inaccurate diagnosis often leads to ineffective treatments and high healthcare costs. Aclarion’s AI-driven approach offers a more precise diagnostic tool, potentially reducing unnecessary surgeries and improving patient outcomes. The triple-digit utilization growth suggests accelerating adoption of the technology, which could disrupt the traditional diagnostic workflow and create new efficiencies in spine care.
The expansion of the commercial team, particularly in the Western U.S., indicates that Aclarion is scaling its sales and support infrastructure to meet rising demand. This hiring and inducement grant suggest confidence in the company’s growth trajectory and the market’s acceptance of Nociscan. For investors, the stock option grant aligns Keefe’s incentives with long-term shareholder value, as the vesting schedule ties compensation to continued employment and performance.
However, the company’s forward-looking statements caution that actual results may differ due to risks and uncertainties detailed in its SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025. The inducement grant underscores Aclarion’s commitment to building its commercial presence, but the technology’s ultimate impact will depend on continued clinical validation, market adoption, and competitive dynamics in the healthcare AI space.
For more information about Aclarion and its Nociscan platform, visit www.aclarion.com. The latest updates on $ACON are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.
